KPV dosage calculator
KPV (α-MSH 11-13 fragment) dosage calculator with reconstitution math for 5mg and 10mg lyophilized vials. Anti-inflammatory tripeptide for gut, skin, and systemic research protocols. Live U-100 insulin syringe draw.
How to use this KPV dosage calculator
This KPV dosage calculator runs reconstitution math live for the most common research KPV vial sizes — 5mg and 10mg lyophilized vials — and returns the exact mark to draw to on a 1mL U-100 insulin syringe. The defaults above (5mg vial, 1mL bacteriostatic water, 500mcg target dose) match a standard KPV protocol and pull to the 10-unit mark on a U-100 syringe.
Pick your KPV vial size
KPV ships in 5mg or 10mg lyophilized vials from most research suppliers. The 5mg vial is the most common format and typically covers a 10-day protocol at 500mcg daily. The 10mg vial extends coverage and is more cost-effective per mg for long protocols or multi-peptide users.
Pick your BAC water volume
KPV reconstitutes cleanly at 1mL of bacteriostatic water for a 5mg vial — a 5 mg/mL concentration where a 500mcg dose pulls to 10U on a U-100 syringe. The 10mg vial reconstituted with 2mL yields the same 5 mg/mL concentration with double the total volume. Lower BAC ratios produce harder-to-read small draws.
Set your KPV target dose
KPV is dosed in micrograms — switch the unit toggle to mcg. Common research doses range from 200 mcg to 1 mg per day depending on protocol. Enter your dose and the calculator returns U-100 units, injection volume, concentration, and doses per vial.
Read the U-100 syringe units
Pull the plunger to the indicated unit mark on a 1mL U-100 insulin syringe. At default settings (5mg/1mL/500mcg dose), the draw is 10U. The visual syringe shows the fill in real time — drag it directly to scrub through doses live.
The full protocol in your pocket.
Reconstitution math is step one. Running a peptide protocol means reminders, rotation, adherence, and history. PeptideMaxxers handles all of it — offline-first, privacy-first, native SwiftUI.
This calculator handles the math. The app handles the protocol.
KPV peptide dosage and reconstitution guide
KPV is a tripeptide composed of lysine-proline-valine — the C-terminal fragment (residues 11–13) of α-melanocyte-stimulating hormone (α-MSH). It retains the anti-inflammatory activity of the parent α-MSH molecule while lacking the pigment-stimulating and appetite-modulating effects of the full peptide. KPV is used as a research peptide for anti-inflammatory applications, particularly in gut health (IBD research), skin inflammation, and wound healing contexts. This guide covers KPV dose math, the dosing protocol by purpose, reconstitution at 5mg and 10mg vial sizes, half-life, delivery route options (subcutaneous, oral, topical, sublingual, suppository), side-effect profile (minimal — KPV has a particularly clean safety profile), and the practical answers to the most-asked KPV dosage questions.
KPV dosage chart by purpose
KPV is typically dosed at 200 mcg to 1 mg per day via subcutaneous injection, though oral and topical routes are used for gut and skin protocols respectively. Doses below are common values from research literature and community protocols, not medical recommendations.
| Research purpose | Daily dose | Frequency / route | Typical cycle |
|---|---|---|---|
| General anti-inflammatory research | 500 mcg | 1× daily, subQ | 4–8 weeks |
| Gut / IBD research | 500–1000 mcg | 1× daily, subQ or oral | 8–12 weeks |
| Gut-specific (oral capsule) | 500–1000 mcg | 1–2× daily, oral | 8–12 weeks |
| Skin inflammation research | 250–500 mcg | 1× daily, topical (0.5–1% cream) | 4–8 weeks |
| Wound healing research | 500 mcg | 1× daily, subQ near-site | 2–4 weeks |
| Acute anti-inflammatory | 1 mg | 1× daily, subQ | 2–4 weeks |
KPV concentration matrix — vial size × BAC water
Auto-generated from supplier vial sizes against the standard BAC water volumes. Use this to choose your reconstitution before you draw.
| Vial size | 1 mL BAC | 2 mL BAC | 3 mL BAC | 5 mL BAC |
|---|---|---|---|---|
| 5 mg | 5.0 mg/mL | 2.5 mg/mL | 1.7 mg/mL | 1.0 mg/mL |
| 10 mg | 10.0 mg/mL | 5.0 mg/mL | 3.3 mg/mL | 2.0 mg/mL |
Draw units at common KPV doses
U-100 insulin syringe units to draw, computed at the most common KPV reconstitution (1mL BAC water).
| Vial (at 1mL BAC) | 200 mcg | 500 mcg | 750 mcg | 1000 mcg |
|---|---|---|---|---|
| 5 mg | 4.0 U | 10.0 U | 15.0 U | 20.0 U |
| 10 mg | 2.0 U | 5.0 U | 7.5 U | 10.0 U |
KPV reconstitution — 5mg and 10mg vials
The 5mg lyophilized vial is the standard KPV research format. Reconstitution at 1mL of bacteriostatic water yields a 5 mg/mL concentration where a 500mcg dose pulls to 10U on a U-100 syringe and a 1mg dose pulls to 20U. The 10mg vial reconstituted with 2mL also yields 5 mg/mL at double the total volume — the practical choice for long protocols.
KPV delivery routes — subQ, oral, topical, sublingual
KPV's tripeptide size (just 3 amino acids) makes it unusually versatile across delivery routes. Subcutaneous (subQ) injection is the standard route for systemic dosing and is the reference route for the dosing math above. Oral KPV (enterically coated capsules compounded by research pharmacies) targets the GI tract directly and is the preferred route for IBD/gut research protocols — the small peptide survives partial GI breakdown and acts locally on inflamed mucosa. Topical KPV (compounded into a 0.5–1% cream base) targets skin inflammation directly with minimal systemic absorption. Sublingual KPV (a few drops of reconstituted solution held under the tongue) is a needle-free systemic alternative with reduced but meaningful bioavailability. KPV suppositories exist for distal colonic IBD research where direct rectal application concentrates the peptide at the inflammation site.
KPV half-life and dosing timing
KPV has a serum half-life of approximately 3 hours — short, but the anti-inflammatory signaling effect outlasts serum presence because KPV triggers downstream transcriptional changes (NF-κB pathway modulation) that persist hours after the peptide itself has cleared. Once-daily subQ dosing is the standard pattern. Some protocols split the dose (250mcg twice daily) to maintain more continuous receptor activation, though evidence for split-dose superiority is limited. Timing relative to meals does not materially affect subQ dosing; for oral routes, empty-stomach or pre-meal dosing is typical.
KPV mechanism — α-MSH 11-13 fragment
KPV is the lysine-proline-valine tripeptide corresponding to residues 11–13 of α-melanocyte-stimulating hormone (α-MSH). α-MSH itself has broad activity across multiple melanocortin receptors (MC1R through MC5R) producing pigmentation, appetite suppression, and anti-inflammatory effects together. KPV fragment-studies have shown that the C-terminal tripeptide retains the anti-inflammatory signaling (via MC1R and through NF-κB pathway inhibition) while lacking the pigmentary and appetite effects of the full molecule. This mechanism is why KPV is used specifically for anti-inflammatory research: it captures α-MSH's therapeutic anti-inflammatory activity without the broader melanocortin side-effect spectrum that would make full α-MSH impractical as a pure anti-inflammatory.
KPV side effects and safety profile
KPV has a particularly clean safety profile in research literature. Because it's a 3-amino-acid fragment of an endogenous human peptide, the tolerability data shows minimal adverse events across subcutaneous, oral, topical, and sublingual routes. Common observations: mild injection-site irritation (redness, brief stinging) with subQ administration, no significant reports of systemic effects at standard 500mcg–1mg doses. KPV does not produce the pigmentation changes associated with full α-MSH because the pigmentary-active sequence (residues 4–10 of α-MSH) is not present in the KPV fragment. Oral KPV can produce transient GI changes during the first 1–2 weeks of IBD research protocols as the gut mucosa responds. There are no documented drug interactions of concern at standard doses.
KPV + BPC-157 stack
KPV and BPC-157 are frequently stacked for gut-healing protocols. The mechanisms are complementary: BPC-157 promotes tissue repair and angiogenesis through growth factor modulation; KPV suppresses the inflammatory signaling (NF-κB) that perpetuates chronic gut inflammation. The combination addresses both the damage-repair and the inflammation-driver axes of conditions like IBD research. Common stack: BPC-157 at 250–500 mcg daily subQ alongside KPV at 500 mcg daily subQ (or oral KPV at the same dose for gut-local action). Some formulations (Klow and related blends) pre-combine KPV with BPC-157 and GHK-Cu in a single vial — the Klow blend calculator handles the blend math.
KPV cycle length
KPV cycles typically run 4–12 weeks depending on the protocol target. Acute anti-inflammatory applications: 2–4 weeks. General systemic anti-inflammatory research: 4–8 weeks. Chronic gut research (IBD): 8–12 weeks. There is no documented tolerance or receptor desensitization with KPV, so cycles can be repeated with short breaks (1–2 weeks) between runs. Some users continue KPV indefinitely at maintenance doses (250 mcg daily) for ongoing anti-inflammatory support — KPV's clean safety profile makes this tenable in ways that more complex peptides are not.